Featuring an interview with Dr Hanny Al-Samkari, including the following topics:

• Mechanism of action and toxicity of the monoclonal antibody ianalumab (0:00)
• Primary results from VAYHIT2, a randomized, double-blind Phase III trial of ianalumab with eltrombopag for patients with primary immune thrombocytopenia (ITP) after failure of first-line corticosteroid treatment (7:32)
• Mechanism of action and toxicity of the Bruton tyrosine kinase inhibitor rilzabrutinib (11:52)
• Reduction in corticosteroid use with rilzabrutinib and sustained response in adults with persistent or chronic ITP in the long-term extension period of the Phase III LUNA3 study (18:46)

CME information and select publications

Featuring perspectives from Dr Hope S Rugo and Dr Sara M Tolaney, including the following topics:

• Introduction: Long-Term Outcomes with Antibody-Drug Conjugates (0:00)
• HER2-Positive Breast Cancer (8:02)
• HER2-Negative Breast Cancer (32:41)

CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Antibody-Drug Conjugates for Breast Cancer | Faculty Presentation 2: Current and Emerging Role of TROP2-Directed ADCs — Sara M Tolaney, MD, MPH

CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Antibody-Drug Conjugates for Breast Cancer | Faculty Presentation 1: Current and Emerging Role of HER2-Directed Antibody-Drug Conjugates (ADCs) — Hope S Rugo, MD

CME information and select publications

Featuring perspectives from Dr Luis Paz-Ares and Dr Misty Dawn Shields, including the following topics:

• Introduction: Rational Treatment Goals for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)? (0:00)
• Current Considerations in the Selection of First-Line and Maintenance Therapy — Dr Borghaei (8:13)
• Case: A woman in her early 60s newly diagnosed with ES-SCLC who receives first-line atezolizumab/EP and maintenance atezolizumab with delayed addition of lurbinectedin — Dr Borghaei (16:21)
• Case: A woman in her mid 60s with multiple comorbidities newly diagnosed with ES-SCLC who receives first-line atezolizumab/etoposide and maintenance atezolizumab/lurbinectedin with discontinuation of lurbinectedin — Dr Borghaei (23:46)
• Clinician Survey Results (32:16)
• Case: A woman in her early 70s with multiple comorbidities and newly diagnosed ES-SCLC with TP53 and RB1 mutations who receives first-line atezolizumab/etoposide and maintenance atezolizumab/lurbinectedin — Dr Chiang (41:39)
• Case: A man in his mid 70s with multiple comorbidities and a history of limited-stage SCLC managed with chemoradiation therapy who enrolls in the DeLLphi-312 trial upon disease recurrence — Dr Chiang (47:20)
• Promising Investigational Strategies — Dr Chiang (49:14)

CME information and select publications

Featuring an interview with Dr Stacey A Cohen, Dr Arvind Dasari and Dr Christopher Lieu, including the following topics:

• Biological Principles Underlying Circulating Tumor DNA (ctDNA) Molecular Residual Disease (MRD) Testing in Colorectal Cancer (CRC) — Dr Cohen (0:00)
• Potential Utility of ctDNA Testing to Identify Patients with Localized CRC Who Might Benefit from Treatment De-escalation or Escalation — Dr Lieu (17:44)
• Role of ctDNA Analysis in the Management of Metastatic CRC – Dr Dasari (36:16)
• Clinical Investigator Survey Results (56:06)
• Case: A woman in her early 40s with mismatch repair-proficient/microsatellite-stable (MSS), low-risk Stage II colon cancer — Dr Lieu (1:23:05)
• Case: A woman in her early 70s with microsatellite instability-high Stage III colon cancer with a BRAF mutation — Dr Cohen (1:26:06)
• Case: A man in his mid 40s with metastatic CRC — Dr Dasari (1:31:57)
• Case: A man in his early 50s with low-risk Stage III colon cancer — Dr Lieu (1:37:54)
• Case: A man in his early 30s with MSS, high-risk Stage II CRC — Dr Cohen (1:50:17)
• Case: A woman in her early 50s with metastatic CRC — Dr Dasari (1:52:05)
• Case: A man in his early 60s with Stage IV colon cancer — Dr Lieu (1:56:05)

CME information and select publications

Featuring an interview with Dr Terence Friedlander, including the following topics:

• Perioperative durvalumab with neoadjuvant chemotherapy: Health-related quality-of-life outcomes in the NIAGARA trial (0:00)
• Targeting HER2 in locally advanced or metastatic urothelial carcinoma (5:17)
• TROP2-targeted antibody-drug conjugates for locally advanced or metastatic urothelial carcinoma (18:19)

CME information and select publications

Featuring perspectives from Dr Natalie S Callander and Dr Paul G Richardson, including the following topics:

• Introduction: Clinical Trials We LOVE to Discuss (0:00)
• Mechanism of Action of Cereblon E3 Ligase Modulators (CELMoDs) (8:42)
• Available Efficacy Data with CELMoDs in the Management of Relapsed/Refractory Multiple Myeloma (MM) (15:59)
• Extramedullary Disease (19:23)
• Spectrum and Management of CELMoD-Associated Adverse Events (30:12)
• Ongoing Phase II and III Trials Evaluating CELMoDs for MM (34:53)

CME information and select publications

Featuring patient case presentations by Dr Fern Anari and Dr Catherine Fahey, with commentary from Dr Matthew D Galsky, including the following topics:

• Case: A man in his early 60s with urothelial bladder cancer (UBC) is found to have metastatic disease shortly after surgery (0:00)
• Case: A man in his late 70s experiences disease progression after first- and second-line treatment for metastatic disease (7:39)
• Case: A fit man in his early 70s presents with metastatic disease (15:22)

CME information and select publications

Featuring perspectives from Dr Terence Friedlander and Dr Rana R McKay, including the following topics:

• Introduction (0:00)
• Up-Front Treatment of Ovarian Cancer (OC) (1:13)
• Management of Platinum-Resistant OC (11:49)
• Up-Front Management of Metastatic Endometrial Cancer (32:42)
• Management of HER2-Positive Gynecologic Cancers (45:11)
• Management of Cervical Cancer (53:10)

CME information and select publications